Eilean Therapeutics Unveils In Vivo Results for TE205 MALT1 Degrader Targeting Ulcerative Colitis Eilean Therapeutics showcases its innovative drug TE205 at a major conference, demonstrating significant potential for treating ulcerative colitis through unique mechanisms.

Eilean Therapeutics Unveils In Vivo Results for TE205 MALT1 Degrader Targeting Ulcerative Colitis #United_States #Las_Vegas #Eilean_Therapeutics #MALT1 #TE205

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion NASDAQ:RXRX, a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first pati...

#RXRX
#Recursion Announces First Patient Dosed in Phase 1 Clinical Study of #REC-3565, a Selective #MALT1 Inhibitor for #Relapsed or #Refractory #B-cell #Lymphomas

www.tradingview.com/news/reuters...